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1. Introduction  
 
RNAi-based therapeutics hold tremendous 
promise as novel and potentially more effective 
treatments for cancer.  Small Interfering RNA 
(siRNA) and microRNA (miRNA) are two main 
types of interferencing small RNAs that modu-
late gene expressions and are believed by some 
investigators to be potential “superdrugs”, 
thereby extensive investigation efforts have 
been directed to impel siRNA and miRNA into 
clinical therapeutic applications, and many clini-
cal trials are ongoing.   
 
The mechanism of RNA interference has been 
extensively studied.  RNAi is the highly specific, 
homology dependent suppression of gene ex-
pression by small double-stranded RNA 
(dsRNA).  Upon entering a cell, dsRNA is cleaved 
by the enzyme Dicer, into fragments of 21-mer 
mature siRNA to silence its target gene expres-
sion [1-5].  Available RNAs for gene interference 
might expand to other endogenous short RNAs 
that are becoming clear in mechanism and also 
show the potential for RNA interference such as 
piRNAs and esiRNAs [6]. 
 
The potent, sequence-specific gene silencing by 
RNAi has become a powerful tool in biomedical 
research and holds significant potential as 
novel molecular therapeutics for cancer [5, 7] 
and other diseases such as hepatitis C virus 
infection and myocardial disease [8-10]. RNAi 
can be induced in mammalian cells by the intro-
duction of synthetic double-stranded siRNAs or 
by plasmid and viral vector systems that ex-
press double-stranded short hairpin RNAs 
(shRNAs), which are subsequently processed 
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into siRNAs by cellular machinery [5].  RNAi se-
lectively downregulates its target pathological 
proteins, without being associated with the limi-
tation the conventional therapeutic approaches, 
such as extensive systemic toxicity [11].  siRNA 
is reported to be more potent than conventional 
anti-sense strategies in inhibiting target gene 
expression and seems less toxic in vivo [12].   
 
However, the promise of RNAi as cancer thera-
peutics is hampered by difficulties in the deliv-
ery of the siRNA molecules to the target cells in 
vivo because these molecules are extremely 
hydrophilic, sensitive to RNAse degradation and 
comparatively large [3, 5, 13, 14].  Low trans-
fection efficiency, poor tissue penetration, and 
nonspecific immune stimulation by siRNAs ad-
ministered in vivo have hindered therapeutic 
applications.  Success of RNAi as therapeutics 
against diseases such as cancer hinges on the 
availability of a delivery vehicle that is tumor-
specific and can be administered systemically, 
safely and repeatedly.  Currently, three different 
kinds of RNAi delivery systems have been ex-
plored: modified naked RNA, viral vectors and 
non-viral vectors.  Among these delivery sys-
tems, modified naked RNA best avoids an im-
mune response and increases uptake by cells 
compared to naked RNA, but general chemically 
modified naked RNA lacks tumor targeting and 
specificity, thus a large amount of the RNA is 
needed to reach high efficiency [15].  Viral vec-
tors show high gene transfer efficiency but are 
deficient in their ability to target specific cells.  
Their residual viral elements can also be immu-
nogenic, cytopathic, or recombinogenic [16].  
Non-viral vectors are constructed with biocom-
patible materials such as polymers, liposomes, 
peptides and proteins, and polysaccharides 
using innovative fabrication approaches that 
aim to safely transport RNA for increased trans-
fection efficiency [16, 17].  However, applica-
tions of non-viral delivery systems are still con-
strained by those problems such as: low pack-
aging efficiency, low colloidal stability, target cell 
internalization, endosomal escape, and com-
paratively low gene transfer efficiency. 
 
Hence, for both viral and non-viral vectors, the 
three main difficulties associated with utilizing 
RNA-based therapeutics for clinical treatment 
remain to be the “delivery, delivery, and deliv-
ery” [18]. The challenge derives mainly from the 
complexity of the physiological environment in 
tissues and cells, combined with the unique 
properties of RNAs.  These barriers exist and 
vary from case to case because of the different 
microenvironments of human tissues, the diver-
sity of RNA species, and the specific ap-
proaches of administration.  So far, great efforts 
have been directed towards overcoming the 
issues associated with delivery for RNAi.  While 
some significant achievements have been 
made, there remains a huge gap between cur-
rent progress and the ideal systemic delivery of 
RNAi.  To gain insights and improve the effi-
ciency and specificity of non-viral delivery sys-
tem, extensive research is on-going aiming to 
overcome the RNAi delivery barriers one by one.  
 
Development of current pharmacology technol-
ogy has advanced many new drugs into clinical 
applications. Drug delivery systems have gained 
extensive achievements with great improve-
ment of the drug efficiency aided by diverse 
carriers which have been widely reviewed [19-
22].  RNA vectors share the same basic require-
ments with other drug delivery carriers such as 
biocompatibility, long-time stability remaining in 
body, and targeted delivery, therefore the gen-
eral advancements of drug carriers in overcom-
ing delivery barriers could also benefit the fabri-
cation of RNAi vectors.  However, specific prop-
erties of RNA pose unique requirements and 
these problems need to be carefully addressed 
when designing non-viral nanovectors for RNAi-
based therapies.  
 
Up to now, various kinds of vectors have 
emerged and many reviews have referred to the 
advancement of vectors from different points of 
view [23-25].  In this review, we summarize the 
existing delivery barriers together with the re-
quirements to overcome these problems, and 
focus on the current progress and future direc-
tion of the non-viral nanovectors serving in tu-
mor-targeted RNAi for cancer therapy.  
 
2. Administration Routes and Associated Barri-
ers  
 
Barriers to RNA delivery are highly dependent 
on administration routes [26].  Different barriers 
might be encountered in respect to different 
administration routes, thus it would be the pri-
mary consideration on current different admini-
stration approaches possible for RNA vector 
delivery when crossing these delivery barriers.  
A number of general administration routes have 
been attempted for gene delivery including local 
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injection [27], intranasal delivery [28], intrathe-
cal injection [29, 30], oral delivery [31], intrap-
eritoneal injection [32] and intravenous injec-
tion [27, 33].  Other administration routes have 
also been demonstrated such as intravitreal 
injection [34],  intraventricular injection [35],  
and intraperitoneal injection [36].  Typical 
routes of administration are discussed as be-
low. 
 
2.1. Local injection 
 
Local injection is the easiest way to achieve a 
high concentration of vectors to the disease 
tissue such as a tumor and also minimizes com-
plications in the circulatory system compared to 
other delivery routes.  Other advantages include 
easy manipulation and time-saving, both of 
which are attractive for RNAi delivery. However, 
local injection suffers from the limited ability to 
apply this administration route only to certain 
accessible tissues, for example, skin cancer or 
head and neck cancer.  
 
2.2. Intranasal delivery 
 
The intranasal route is an easier, inexpensive, 
and especially non-invasive delivery approach.  
The nasal mucosa provides advantages as a 
target route for drug delivery, including large 
surface area for delivery, rapid drug onset, po-
tential for central nervous system delivery, and 
no first-pass metabolism.  Furthermore, the in-
tranasal route shows potential to overcome the 
brain-blood-barrier due to of the special associa-
tion between nasal mucosa and the brain.  Di-
rect instillation of RNA through intranasal route 
is incomparably superior for application to tis-
sues within the respiratory system, such as ena-
bling direct contact with lung epithelial cells, 
which play a significant role in lung diseases 
and infections, including cystic fibrosis, asthma, 
influenza and the common cold, and potentially 
lung cancer [24]. 
 
2.3. Oral delivery 
 
Oral delivery is a preferred way to transport RNA 
vectors to various tissues of the body.  Because 
of its versatility, ease of use, and non-invasive 
properties, the oral delivery approach is given 
priority in clinical therapeutics and drug devel-
opment.  However, orally delivered vectors re-
quire time to circulate the body before entering 
target sites.  Furthermore, vectors in the oral 
pathway are directly exposed to the stomach 
microenvironment and must be designed to 
remain stable in acid fluid and avoid degrada-
tion by digestive enzyme such as pepsine and 
gastric lipase.  Vectors that are absorbed 
through the intestine must be designed to pene-
trate across the mucus barrier and withstand 
first-pass metabolism, avoiding a significant 
decrease in the vector concentration at the dis-
ease tissue site due to its absorption by the 
liver.  
 
2.4. Intravenous delivery  
 
Compared to other administration routes, intra-
venous injection rapidly delivers nanovectors to 
the most tissues throughout the whole body.  
Although invasive, it is the most popular way 
employed in clinical treatment due to its rapid-
ness and bioavailability.  However, vectors 
transported through intravenous injection still 
encounter a fair amount of barriers; from the 
moment the vectors are injected into the ves-
sels, challenges arise from the contents in the 
blood, organs of the circulatory system, epider-
mis cells or mucus cells, tissue junction, and 
immune cells.  
 
2.5. Intraperitoneal injection 
 
Intraperitoneal injection is one of the most com-
mon substitutions for intravenous injection.  
Certain chemotherapy drugs have been applied 
in intraperitoneal injection.  A recent study indi-
cates that siRNA injected through this approach 
accumulate more in the spleen and liver but 
less in the kidneys [26].   
 
2.6. Intrathecal injection 
 
Drugs injected into the spinal canal avoid the 
blood brain barrier present with the intrathecal 
injection and are able to directly interact with 
nerve system tissues and cells.  However, drugs 
and RNA vectors used in the intrathecal injec-
tion must be specially treated to eliminate pre-
servative or other poisonous contaminants 
which could provoke serious adverse effects 
specifically to the nerve system.  Thus, intrathe-
cal injection requires a higher level of vector 
and RNA material purity and safety than other 
administration routes. Currently, some anti-
tumor drugs such as methotrexate, cytarabine 
(a.k.a. Ara-C) and hydrocortisone have been 
used for intrathecal injection, and others such 
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as vincristine might cause serious side effects, 
hence the intrathecal injection of RNAi vector 
should be cautious.  
 
Generally, the delivery barriers for all adminis-
trative pathways can be categorized into four 
segments: long-time stability, penetration into 
the tissue, targeting of the desired site and en-
tering the cells, release of the drugs and inter-
ference function. While each of these four basic 
barriers exist in each administrative route, the 
level with which each barrier presents itself var-
ies by route.  
 
Firstly, long-term stable dispersion requires the 
nanovectors be protected from kidney filtration, 
uptake by phagocytes, aggregation with serum 
proteins, evoking of T cells or B cells (except 
intentionally), and enzymatic degradation.  
 
Secondly, penetration into the tissue needs to 
overcome the vascular endothelial barrier pri-
marily. Besides the capillary endothelium, other 
adhesive surface coating molecules still need to 
be addressed.  For example, the mucus layer is 
a highly viscoelastic barrier designed to trap 
foreign molecules and then move the drugs out 
with mucus clearance mechanism [37].  Capil-
lary endothelium typically allows molecular 
penetration for molecules below 5nm in diame-
ter and most of big molecule can not across 
until they are cleared out of the body.  Only a 
few tissues such as tumor sites, liver and 
spleen allow the penetration of large molecule 
up to 200 nm in diameter.  In general, extensive 
efforts are needed to address this barrier before 
whole-body treatments can be achieved. 
 
Thirdly, after penetration across the capillary 
endothelium, RNAi nanovectors should target 
certain cells for specific cell transfection. Tar-
geted delivery of drugs or RNAi minimizes un-
wanted uptake by other cells, and thus in-
creases the drug concentration in the target 
tissue even in cases where drugs are circulating 
throughout the body.  It also lessens adverse 
effects from treatment and allows for both high 
transfection efficiency and quick transfection 
function.  It may also be possible to track free 
tumor cells dispersed in the blood through tar-
geted delivery.  The overall process depends on 
the nanovector recognizing and attaching to 
certain cell surfaces.  To fulfill the assignment 
of siRNA and miRNA, vectors penetrate through 
the cell membrane with the assistance of some 
molecules or by endocytosis of cells, which is 
recognized as membrane transportation.  
 
When nanovectors are internalized into cell via 
the endosome pathway, the nanovectors must 
break from the endosome before the endosome 
changes into a lysosome in a lower pH environ-
ment.  Not doing so would degrade the vector or 
RNA.   
 
In addition to the above mentioned require-
ments, there are still some other issues regard-
ing nanovector delivery that need to be ad-
dressed such as the adverse effects of certain 
RNA and the toxicity of vector’s nanomaterials. 
 
3. Efforts and Solutions towards Barriers  
 
3.1. Long-term stability of RNAi nanovectors in 
vivo  
 
One of the biggest problems associated with the 
use of RNAi nanovectors is the inability of any 
delivery system to guarantee that all cancer 
cells take up the nanovectors.  No single vector 
or method reported so far can transfect all tar-
get cells, and this could be a potential problem 
for some clinical treatments.  For example, in a 
tumor, cancer stem cells, which account for only 
about 1% of the total cancer cells, can differen-
tiate into progenitor and mature tumor cells; 
and the tumor will continue to grow as long as 
those minority cancer stem cells are left un-
harmed [38-40].  Thus the current goal is to 
elongate the vectors’ bioavailability and life 
span, and to increase targeted delivery of the 
nanovector as much as possible.  Currently, 
long-term bioavailability acts against the body’s 
defense system which includes serum protein 
discrimination and agglutination, enzyme degra-
dation, defense of immune system and metabo-
lism system.  
 
3.1.1. Avoiding protein agglutination, enzyme 
degradation and macrophage uptake:  Polymer 
modification 
 
Regardless of the administration route em-
ployed, the RNAi nanovectors should be physi-
cally and chemically stable towards serum pro-
tein agglutination and enzymatic degradation in 
the circulatory system until RNAs are released 
to function in cells.  Basically, protein agglutina-
tion or enzymatic degradation involves the 
molecule recognition of the RNAi nanovectors. 
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The physicochemical properties of the nanovec-
tors’ surface, including particle size, surface 
charge and surface functionality, have an impor-
tant effect on the bioavailability of the nanovec-
tors.  To decrease the possibility of unspecific 
protein and enzyme agglutination, various poly-
mer coating materials have been tested and the 
most popular polymer material to avert un-
wanted protein disturbance is PEG modification 
[41-43].  PEG-coated particle have shown to 
decrease hemolytic activity, platelet aggregation 
and activation, and complement activation as 
reviewed [44].  Surface polymer coating such as 
PEG demonstrated the ability to significantly 
decrease recognition by immune cells and could 
prolong nanoparticle circulation in the blood, 
decreasing uptake by resident phagocytes in 
spleen and liver [45, 46]. Surface PEG coating 
sterically hinders the interaction and binding of 
blood components with the vector surface and 
could also prevent drug carrier opsonization and 
capture [41, 47, 48].  
 
Currently, non-viral micelles nanovectors pre-
pared with amphiphilic polymer generally em-
ploy PEG as a hydrophilic chain, which is com-
monly recognized as an effective way to avoid 
protein interaction.  Diverse PEG-modified am-
phiphilic copolymers have been employed to 
construct amphiphilic hydrogel, micelles, and 
nanoparticles [49-51].  Recent development of 
recombinant polypeptide showed potential sub-
stitution for PEG coating to increase the half-life 
when shielding peptide and protein.  Schellen-
berger et al. [52] demonstrated a recombinant 
polypeptide containing 864 amino acids that 
could effectively prolong the plasma half-life of 
peptides to 139 hours.  The bioengineering with 
various length of amino acid chain could have 
an impact on the half-life of the linked protein 
and peptides. 
 
3.1.2. Fight against kidney filtration and hepa-
tobiliary processing 
 
During their suspension in the circulatory sys-
tem, nanovectors are likely to be cleared from 
the body by two main mechanisms.  One is the 
filtration by the kidneys into urine and the other 
is hepatobiliary processing into bile.  To avoid 
the kidney filtration, certain criteria should be 
followed with respect to the physiochemical 
properties of the nanovectors, including the 
particle size and shape, surface charge and 
surface chemistry [53].  The kidney clears the 
waste depending on the diameter of particles, 
and the particles with a diameter less than 8 
nm could be easily subjected to the filtration 
process.  Nanovectors which do not undergo 
kidney filtration may subject to hepatobiliary 
processing.  Some research has referred to the 
clearance of nanoparticles by metabolism sys-
tem.  Polymers and dendrimers less than 8nm 
primarily undergo renal clearance.  Quantum 
dots (QDs) with less than 5.5 nm and zwitteri-
onic coatings demonstrated a rapid renal clear-
ance [54].  Liposome-based nanovectors pri-
marily undergo hepatobiliary clearance.  Metal-
containing nanoparticles are cleared primarily 
through hepatobiliary clearance.  Small com-
plexes containing an oligonucleotide with a mo-
lecular weight less than 5000 kDa would be 
easily ultrafiltered by renal glomerulus and can-
not be re-uptaken [55].  Nanovectors injected 
into the body should be engineered to fight 
against kidney and hepatobiliary processing 
prior to RNA release, while biodegradable 
nanovectors should be designed to be excreted 
by the body after RNA interference and degrada-
tion of vectors. 
 
3.2. Cross the vascular endothelial and mucus 
barrier  
 
The capillary endothelium sets up the first tight 
physical barrier as the RNAi nanovectors circu-
lating from the circulatory system to the tissue.  
From observation, the largest molecule able to 
penetrate the capillary endothelium is less than 
5nm in diameter and most big molecules can-
not across.  Only a few tissues, such as those of 
the liver, spleen and some tumor sites, allow 
penetration by a large molecule up to 200 nm in 
diameter.  In these tissue sites, the endothelial 
barrier does not present as a problem, but in 
other organs, nanovectors with a diameter of 
more than 5nm should be designed to cross the 
vascular endothelial.  In solid tumors, preferen-
tial accumulation of macromolecules such as 
siRNA complex may be contribute to enhanced 
permeability and retention (EPR) effect, which is 
attributed to the abnormal tumor blood vessel 
and some factors are known to assist in this 
effect, such as vascular endothelial growth fac-
tor, bradykinin, and peroxynitrite, etc.  
 
Extracellular matrix, the dense networks of poly-
saccharides and fibrous proteins can create 
serious resistance against the transportation of 
macromolecules and nanoparticles.  These ma-
trix also create a layer of viscoelatic and adhe-
sive gel that exists widely in the lungs, gastroin-
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testinal system, vagina, eye and other mucosal 
surfaces.  Nanoparticles designed to penetrate 
the mucus layer in these areas must avoid ad-
hesion to mucin fibers and be small enough to 
avoid significant steric inhibition.  Nanoparticles 
have been engineered to penetrate the mucus 
by channeling through low viscosity pores (refer 
to the recent reviews on mucus properties and 
corresponding mucus-penetrating drug delivery 
systems [37, 56]).  Some studies shows that 
short chain and dense PEG-coated particles 
have improved transport rates, which has im-
portant implications for the development of 
therapeutics and imaging applications in vivo 
[57, 58].  In addition to PEG-modification, poly-
saccharide chitosan, a deacetylated derivative 
of chitin that contains cationic glucosamines, 
also appears to facilitate mucoadhension [59] 
and mucopermeation [60].   
 
3.3. Target tissues and cells 
 
Tumor cell targeted delivery of RNAi nanovec-
tors may administer RNAi therapy specifically to 
tumor cells, minimizing adverse side effects and 
improving the efficiency of RNAi.  Targeted deliv-
ery involves three main mechanisms:  enhanced 
drug concentration on target tissues, molecule-
molecule recognition for function on certain 
cells, and external field-guided bio-distribution.   
 
3.3.1. Enhanced drug concentration in certain 
tissues 
 
Enhanced drug concentration in certain tissue 
can be achieved based on the characteristic of 
the tissues or the administration approach.  One 
example is the blood vessels in a tumor, where 
one could observe the enhanced penetration of 
nanoparticles across the abnormal capillary 
endothelium with high drug concentration in 
tumor sites, which is termed as enhanced per-
meability and retention (EPR) effect or the so-
called “passive target” of the tumor.   EPR can 
also be observed in an inflammatory site.  This 
phenomenon is greatly related to bradykinin 
and some molecules such as nitric oxide and 
prostaglandins could also facilitate vessel per-
meability.  The difference between inflammation 
and tumor is the latter prolongs retention time 
due to failure of the lymphatic drainage system.   
Biocompatible macromolecules accumulate at 
much higher (more than six times) concentra-
tions in tumor sites than other tissues and could 
be contained there for weeks.  EPR effect is 
observed for molecules larger than 45kDa, and 
even molecules larger than 800kDa have pene-
trated the tumor vessles [61-63].  Other exam-
ples of enhanced drug concentration on certain 
tissues are related to certain administration 
routes, such as the intranasal and intratracheal 
injection.  Both routes enable direct and en-
hanced drug contact with lung epithelial cells 
[64], and intrathecal injection of nanovectors 
allow them to immediately function in the nerv-
ous system in the spinal canal and  brain. 
 
3.3.2. Molecule-molecule recognition  
 
Diverse molecules and delivery strategies have 
been investigated for their capability to target 
different kinds of cells.  Specific cell characteris-
tics, such as specific or nonspecific molecules 
on the cells or charge properties of cell surface, 
have the potential to be target sites.  For exam-
ple, the cationic surface of the polymer-RNA 
complex facilitates binding to cellular anionic 
proteins and uptake by non-specific endocytosis 
[65].  An enormous database of molecule-
molecule recognition could assist the selection 
and design of target molecules by providing 
analyses and predictions of protein-protein and 
protein-chemical interactions [66]. 
 
However, some small molecules may bind to 
their target through unspecific spatial interac-
tions with structurally similar proteins that may 
not be suitable for target cells, potentially result-
ing in undesirable side effects such as the inhi-
bition of catalytic sites or membrane surface 
receptors. 
 
A wide variety of cell surface ligands are avail-
able for targeted delivery, including antibodies, 
polypeptides, and ligands for diverse surface 
receptors.  So far there are no widely accepted 
tumor-specific antigens or markers available.  
However, some antigens and receptors are not 
universally expressed on all cell surfaces but 
may be over-expressed in certain tumor cells.  
Further investigation of the uniquely expressed 
proteins or markers would greatly improve the 
specificity of tumor-targeting.  
 





Antigens and antibodies have assisted in mole-
cule recognition for decades.  The advantage of 
antigen-antibody recognition is specificity and 
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high affinity that may be exploited for efficient 
and specific RNAi delivery.  Currently, more and 
more antigens and antibodies are being discov-
ered for specific labeling and have been de-
noted in RNA delivery [67-69].  Available anti-
body-based proteomics for human tissue profil-
ing have been reviewed [70-72].  Furthermore, 
monoclonal and polyclonal antibody technology 
provides huge opportunities for the generation 
of commercial antibodies.  Antibody engineering 
has improved the fabrication of smaller recom-
binant antibody fragments and other engi-
neered variants, including diabodies, triabodies, 
minibodies, and single-domain antibodies, 
which are promising alternative candidates to 
monoclonal antibodies. These recombinant frag-
ments still retain the targeting specificity of the 
whole antibodies and hold great potential for 
multivalent and multispecific reagents in tumor 
cell recognition.  
 
3.3.3.2. Aptamer  
 
Aptamers are oligonucleic acids or peptide 
molecules that bind to specific target mole-
cules/receptors. Aptamers have the advantage 
of being chemically synthesized, environmen-
tally stable, and less immunogenic. Available 
aptamers could be classified into two catego-
ries: (1) DNA or RNA aptamers typically con-
structed of short strands of oligonucleotides 
and (2) peptide aptamers consisting of a short 
variable peptide domain attached to a protein 
scaffold at both ends.  Levy et al. demonstrates 
a streptavidin bridge used to bind siRNA to an 
aptamer at the prostate-specific membrane 
antigen expressed in prostate cancer cells and 
the vascular endothelia of tumors [73].  The use 
of aptamers as the targeting molecules has 
been discussed by recent nice reviews [74, 75], 
and there are multiple other examples [76, 77].  
A database of aptamers is also currently avail-
able online.  
 
3.3.3.3. Cell penetrating peptides (Cpp) and 
protein transduction domains (PTD) 
 
PTDs/Cpps are generally peptides less than 30 
amino-acids in length that are able to trigger the 
movement of various biomolecules (plasmid 
DNA, oligonucleotide, siRNA, PNA, protein, pep-
tide, liposome, nanoparticle) across the cell 
membrane into the cytoplasm to improve intra-
cellular routing, thereby facilitate interactions 
with the target cells.  The chemistry and actions 
of Cpps have been extensively reviewed [78-
82], and a few key points are listed here.   
 
Cpps such as Tat, oligo-Arg, transportan and 
penetratin need to be covalently linked to their 
cargoes, and are therefore internalized by cells 
along with their cargoes through endocytosis.  
Cpps that do not need to covalently bind or 
crosslink are able to form stable nanoparticles 
with their cargo due to their amphipathic prop-
erties.  Efforts have been directed towards us-
ing non-covalently linked Cpps carriers to un-
dergo non-endosomal pathways and allow the 
targeted release of cargo into appropriate, de-
sired subcellular organelles. Different types and 
mechanisms of Cpps peptide-nanoparticles 
have been reported [83, 84].  RGD [85] motif is 
abbreviated for arginine- glycine- aspartic acid 
sequence and has been recognized for receptor
-ligand interactions occurring between peptides 
and cell surface integrins specific for tumor ne-
ovesculature.  Circular RGD can enhance the 
tumor targeting and transfection of gene vec-
tors.  RGD-nanoparticle conjugates have also 
been shown to increase capacity to target the 
delivery of nanoparticles to certain tumor tis-
sues [2, 86, 87]. Sugahara et al. [88] proposed 
a strategy of using a tumor-homing peptides 
termed as iRGD (internalizing RGD, with a R/
KXXR/K sequence at C-terminal position) to 
deliver compounds and nanoparticles into tu-
mor tissue. These iRGD motifs go through two 
molecule-dependent processes: integrin-
dependent tumor cell binding and peptide pro-
teolysis, and neuropilin-1-mediated tissue and 
cell penetration and show a significant increase 
in the tumor cell internalization effect compared 
to the conventional RGD sequence.  
 
3.3.3.4. CpG moiety 
 
CpG oligonucleotides could be efficiently inter-
nalized by various immune-response cells such 
as dendritic cells, macrophages and B cells 
through Toll Like receptor 9, thereby arouse the 
innate and adaptive immune responses.  Kortyl-
ewski et al [89] showed that immune response 
could generate anti-tumor microenvironment 
and have tumor therapeutic effects, and some 
examples have shown that targeting lymph 
node by CpG oligonucleotides could generate 
anti-tumor immunity [90, 91].   
3.3.3.5. Cell surface receptor 
 
Cell surface receptors are glycoproteins on the 
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surface of a cell which provide specific binding 
sites for target molecules such as cytokines, 
hormones, growth factors, neurotransmitters, 
and adhesion molecules. Molecules specifically 
bind to a cell surface receptor to generate bio-
logical signals for cellular responses such as 
prolifereation, differentiation, apoptosis, and 
degranulation. 
 
Different cells have specific receptors which 
modulate the bioprocess of molecule transpor-
tation, and recent studies have explored cell-
specific receptors for targeted delivery in RNAi 
delivery [89, 92, 93].  Using different targeting 
ligands, various cell surface receptors were tar-
geted for delivery of nanoparticles, including Toll
-like receptor [89], asialoglycoprotein receptor 
[92] and epidermal growth factor receptor [93].  
These ligands can be proteins, antigens, ago-
nists of oligonuclietides, and other specific 
molecules such as sugar [92], urokinase-type 
plasminogen activator [94], and deslorelin [95].    
   
Some specific ligands for the transferrin recep-
tor (TfR) or folate receptor have been used for 
attachment onto long-circulating RNAi nanovec-
tors and have shown that they can increase the 
transfection efficiency in vitro and in vivo [96, 
97].  TfR is over-expressed on the surface of the 
tumor cells, and antibodies against TfR as well 
as Transferrin protein (Tf) itself are among the 
popular ligands for targeting various nanoparti-
cles to tumors and internalization into tumor 
cells [95, 98-101].   We have developed tumor-
specific, ligand-targeting, self-assembled 
nanoparticle-DNA lipoplex systems designed for 
the systemic gene therapy of cancer (US Pat-
ents No. 6,749,863 and 7,479,276) [100, 
101].  These nanovector systems employ trans-
ferrin or scFv against transferrin receptors as 
tumor-targeting ligands [100, 101].   When us-
ing Tf as a targeting ligand, we obtained the self
-assembled nanovectors at the sizes of 50-
90nm, with highly compact structure and fa-
vored surface charge [100].  These nanovectors 
have novel nanostructures that resembles a 
virus particle with a dense core enveloped by a 
membrane coated with Tf molecules spiking on 
the surface [100].  This nanovector system 
shows promising efficiency and specificity in 
targeted delivery of various genes and anti-
sense oligonucleotides to cancer but not normal 
tissues in vivo.  In the AACR 101th Annual Meet-
ing, Washington, DC, April 17-21, 2010, at the 
Late-breaking Oral Presentation session on clini-
cal trials, Pirollo et al reported the success of a 
first-in-man, Phase I trial of this nanovector, 
TfRscFv-nano-p53 (SGT-53, NCT00470613, 
ClinicalTrials.gov). The nanovectors are well tol-
erated in humans and already showed early 
responses. The exogenous p53 expression was 
observed in human cancer tissues in a SGT-53 
dose-dependent manner, but not in normal tis-
sues.  The study demonstrates that the 
nanovectors are safe and effective to deliver 
gene therapeutics to both primary tumors and 
metastatic lesions.  These unprecedented find-
ings in cancer gene therapy trial subjects repre-
sent a major breakthrough in the field and sug-
gest that delivery of genes to tumors with selec-
tivity is indeed possible (Pirollo, et al, LB-172, 
www.aacr.org).  These results should have appli-
cability to the tumor-targeting delivery of other 
therapeutics including siRNA, miRNA, small 
molecules and chemotherapeutics.  
 
In a recent report [102] of a Phase I study on 
patients with solid cancers, Davis and co-
workers provide the first clinical evidence of 
tumor-targeted RNAi using a targeted nanoparti-
cle RNAi delivery system.  These nanoparticles 
were surface-decorated with PEG to increase 
their circulation time in the body, and with hu-
man Tf as a targeting ligand displayed on the 
exterior of nanovectors to engage TfR on the 
surface of cancer cells.  This report demon-
strates that siRNA-nanoparticles administered 
systemically to human can produce a specific 
target gene inhibition [102]. 
 
In addition to TfR, folate receptors were also 
studied to target tumors [103, 104].  Lectins 
are proteins that recognize and bind to carbohy-
drate moieties of protein molecules 
(glycoprotein) on the extracellular side of the 
plasma membrane [105].  Cancer cells often 
express different glycoproteins compared to 
their normal counterparts.  Therefore, lectins 
could be used as targeting molecules to direct 
drugs specifically to the desired target cells and 
tissues [106].  Other cells surface markers such 
as CD44, EpCAM, CD133 have been identified 
for targeting cancer stem cells, and CA125 and 
PSCA have been successfully used to target for 
colon and prostate cancer cells [107-109]. 
 
3.4. Internalization into the cell  
 
Cells are able to uptake exterior substances via 
different pathways including phagocytosis, pino-
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cytosis, macropinocytosis, and endocytosis.  
Understanding substance internalization path-
ways can facilitate the design and engineering 
of RNA vectors.  In most cases, nanoparticles, 
nanovectors and other RNA-molecule conju-
gates are transported into cells through endocy-
tosis.  
 
Different endocytosis routes need to be ad-
dressed to understand the cell internalization 
mechanisms in the intracellular delivery of oli-
gonucleotides.  Basically, endocytosis includes 
three types: 1) The clathrin-coated pathway.  
Some proteins are found to assist in this proc-
ess such as epsin and dynamin. Examples are 
transferrin receptor and lipoprotein receptor 
mediated endocytosis. In this pathway, en-
dosome encapsulates vectors and goes through 
series pH change to lysosome from pH 5.9-6.0 
in early endosome, pH 5.0-6.0 in late endosome 
to pH 5.0-5.5 in lysosome.  2) The caveolae-
mediated pathway: it contains receptors such 
as glycosyl phosphatidylinositol-anchored pro-
teins (GPI-APs) and Siman viruses 40(SV40) 
that could assist in the formation of caveolae.  
GPI-APs could be transported to the Golgi com-
plex and SV40 is delivered to endoplasmic re-
ticulum by special vehicles termed as 
caveosomes. 3) In clathrin- and caveolin-
independent endocytosis, GPI-APs are internal-
ized and sent to the Gogli complex or recycling 
endosomes [110]. 
 
Different internalization pathways for nanovec-
tors uptake are highly related both to the vec-
tors physical and chemical properties and to the 
delivery system.  For example, cationic-lipid-DNA 
complex are internalized via clathrin-mediate 
endocytosis [111] while PEI polyplexes have 
been shown to involve clathrin and caveolin-
mediated endocytosis [112].  
 
The physicochemical properties respective to 
the determination of the endocytosis pathway 
include particle size and surface charge.  
200nm latex nanoparticles could be internal-
ized by clathrin-mediated endocytosis while la-
ger particles rely on the caveolae-dependent 
pathway [113].  50nm nanoparticles might be 
the most suitable size for cell internalization 
[113-115].  
 
Surface charge of the nanovectors may interact 
with the charged cell surfaces and different out-
comes may result depending on the cell surface 
[116].  Generally, cationic vector surfaces en-
hance interaction with negatively charged cell 
membranes and increase the transfection effi-
ciency.  Different cell lines also have different 
internalization pathways with the same 
nanovector and thus may lead to different trans-
fection efficiencies [117].  
 
In addition to the above mentioned pathways, 
studies have revealed other internalization 
routes, such as fluid phase endocytosis [118], 
and data shows that Cpps were internalized by 
certain cells independent of the endosomal 
pathway [119, 120].  The interaction between 
certain Cpps and the lipid membrane is medi-
ated by the hydrophobic domain, which assists 
in the insertion into the lipid membrane and 
thus decreases the possibility of interaction with 
proteoglycanes for a endosomal pathway [112].  
 
3.5. Escape from endosome to avoid lysosomal 
destruction: “proton sponge” effect 
 
 Upon endocytosis, nanovectors get into en-
dosomes and would be subjected to degrada-
tion when the endosomes are subsequently 
fused with lysosomes.  Escaping from the en-
dosome before it fuses with a lysosome is an 
essential step for nanovectors to avoid enzyme 
degradation.  In the clathrin-coated pathway, pH 
values of the endosome gradually change from 
5.9-6.0 to 5.0-5.5 after fusion with the ly-
sosome.  Behr and others introduced the con-
cept of the ‘‘proton sponge’’ and hypothesized 
that polymers with buffering capacities between 
7.2 and 5.0, such as polyethylenimine (PEI), 
peptides containing lysine, arginine and his-
tidine, could buffer the endosome and poten-
tially induce its rupture [121, 122].  The polyca-
tionic material that has “proton sponge” effect 
could absorb the protons generated by the en-
dosomes’ fusion with lysosomes and thus 
avoids the low pH environment and subse-
quently leads to the collapse of the endosome/
lysosome to release the nanovectors and their 
contents into the cytosol.  
 
The proton sponge effect from amino acid of 
lysine, arginine, and histidine is derived from 
the cationic amino group (lysine and arginine) 
and imidazole group (histidine). Amphipathic 
proteins containing arginine-rich peptides [123], 
histidine rich peptides [124] and poly-lysine, 
such as GALA, MPG, have been used to con-
dense RNAs for endosome escape [125, 126].  
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Besides proton sponge, other molecules also 
have the capacity to destabilize the endosomal 
membrane to assist the nanovector escape.  
Lipids such as L-α-dioleoyl phosphatidyl choline
(DOPC), L-α-dioleoyl phosphatidyl ethanolamine
(DOPE),  and their analogues have been com-
bined into lipid nanovectors to destabilize the 
endosome and enhance transfection efficiency 
[127, 128]. 
 
4. RNAi Nanovector Imaging and Exterior Physi-
cal Energy Guiding  
 
In addition to the above mechanisms of 
nanovector transportation, exterior energy 
guided target delivery has also shown powerful 
influence on the host-nanovector interactions 
and thus increases delivery efficiency.  The 
available exterior energy facilitating nanovector 
delivery includes fluorescent and MRI contrast 
material for image guiding, ultrasonic assisted 
cell uptake, and magnetic field directed deliv-
ery.  At the same time, environmentally sensi-
tive nanovectors that respond to interior or exte-
rior environment changes also demonstrate a 
controlled release effect.  
 
4.1. Fluorescent imaging facilitated delivery 
nanovectors 
 
Fluorescent signals facilitate the imaging and 
sensing of RNA vectors, and some fluorescent 
materials have been used to prepare non-viral 
nanovectors to gain insight into the biodistribu-
tion and biometabolism of the delivery system.  
Multifunctional imaging and therapeutic 
nanovectors have opened new opportunities for 
the treatment of diseases including cancer.  
Organic fluorescein has been used for fluores-
cent imaging for decades and is commercially 
available.  Quantum dots (QDs) are advanced 
fluorescent materials that have recently at-
tracted significant attention.  A number of QD-
based RNAi nanovectors have been tested [44, 
129], and in the construction of RNAi nanovec-
tors, QDs usually serve as a nanoparticle scaf-
fold for attachment and condensation of RNAs 
[44, 130, 131].  Gold nanoparticles are re-
ported to effectively quench conjugated fluoro-
phores through fluorescent energy transfer 
[132], and have been used to detect the fluo-
rescence change and release.  Furthermore, 
gold nanoparticles have also been used to study 
the hybrid nanostructure of the vectors, and 
gold nanoparticle-based RNAi nanovectors have 
shown high transfection efficiency [133-136]. 
 
4.2. Magnetic guiding and imaging 
 
In addition to moleculer recognition-based tar-
geting, the effect of exterior energy on the en-
hancement of targeted delivery and transfection 
efficiency of RNAi nanovectors at the desired 
sites has also been tested.  Magnetic particles 
have been extensively employed for targeted 
delivery of pharmaceuticals through magnetic 
drug targeting [137, 138].  Recently, efforts 
have been made to use biocompatible magnetic 
nanovectors for gene delivery in vivo [27, 139, 
140].  In these systems, therapeutic or reporter 
genes are attached to magnetic nanoparticles, 
which are then transported to the target site/
cells via high-field/high-gradient magnets.  The 
use of magnetic particles requires an external 
magnetic field to get a fast targeting of mag-
netic nanoparticles to reach the target sites.  
Alternatively, magnetic field could be applied to 
trigger the drug release when the drug is encap-
sulated in temperature-sensitive hydrogels. 
 
The most important feature of the magnetic 
nanoparticles is that they could reduce the time 
needed for a successful targeted transfection of 
tumor in the presence of a magnetic field com-
pared with other non-viral nanovectors.  Re-
cently, Yoshihisa et al [27] demonstrated the 
application of exterior and interior magnetic 
fields with respect to the magnetic source out-
side and inside the body for the enhancement 
of transfection efficiency.  The study strongly 
supports the application of magnet field to en-
rich nanovectors at the targeted locations and 
thus obtain a high transfection efficiency. 
 
Another aspect of using magnetic nanoparticles 
is their magnetic resonance (MR) imaging func-
tion. MR imaging is one of the most powerful 
non-invasive imaging modalities and is widely 
used in clinic.  MR imaging is based on the 
property that hydrogen protons will align and 
process around an applied magnetic field [137, 
141, 142].  MR imaging can be used to monitor 
the tumor targeting of magnetic nanoparticles in 
vivo.  
 
4.3. Environment-sensitive nanovectors  
 
Environment-sensitive nanoparticles have been 
developed to be able to release their contents 
based on their environmental change, for the 
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controlled drug release.  These environment-
sensitive properties basically involve pH, redox, 
temperature, light, or ultrasound response.  
Some environmental changes can be generated 
by certain abnormalities of pathological sites, 
which provide the opportunity for the controlled 
drug release in the disease site.  Changes, such 
as the decreased pH environment at the tumor 
or inflammation sites could trigger the release 
of drugs from a pH sensitive carrier in these 
sites. 
 
“Proton-sponge” of pH sensitivity is necessary 
for nanovectors to escape from lysosomes if 
nanovectors are taken up by cells through the 
clathrin-assisted endocytosis.  PEG coating may 
protect nanovectors from macrophage and pro-
tein agglomeration, however, a PEG coating that 
is too tight will reduce the potential for RNA re-
lease and function, thus decreasing transfection 
efficiency.  The pH-sensitive, biodegradable PEG
-coating on RNAi nanovectors may overcome 
this drawback.  Here the polycations and PEG 
are linked via acylhydrazides or pyridylhydrazi-
nes, and the pyridylhydrazone prepared from 
polylysine and propionaldehyde-PEG has shown 
the greatest acid-dependent hydrolysis.  Using a 
polyplex shielded with bioreversible PEG conju-
gates, a 100-fold higher in vitro gene expression 
than the conventional polyplexes was achieved 
with the analogous stable PEG shields [143]. 
 
Besides pH-sensitive carriers, nanovectors sen-
sitive to other environmental factors, such as 
temperature and redox conditions, have also 
been investigated.  Ultrasound has been ap-
plied to enhance transfection efficiency via mi-
crobubbles, and recent reports on cationic lipids 
and polymers indicate that they could also be 
triggered by ultrasound.  Compared with micro-
bubbles, cationic lipids and polymers have 
smaller diameters and more stable formulations 
due to their solid matrix structures.  In the case 
of micellar drug delivery, ultrasonic cavitation 
events create transient holes in the cell mem-
brane, increasing the passive diffusion of mi-
celles and drugs into the cells.  Clumakova et al 
[144] demonstrated the 300 nm PLGA nanopar-
ticle gene vector assisted by 5 min ultrasonic 
treatment produced a significantly greater ex-
pression of the reporter gene in the tumor than 
that without ultrasound.  Liu et al [145] investi-
gated light-responsive cationic vesicles for 
photo-assisted gene delivery, making use of the 
different azobenzene concentrations in the for-
mation of vesicles, thus these vesicles could 
collapse upon UV illumination and release of 
the delivered gene therapeutics.  
 
4.4. Multifunctional nanovectors 
 
Ideal multifunctional RNAi nanovectors should 
be able to: 1) achieve efficient and targeted 
delivery of RNAi to the target cells; 2) track 
nanovectors localization; 3) validate targeting by 
a reporter whether a target is hit; and 4) indi-
cate RNAi efficiency with report/readout of the 
outcome.  Multifunctional nanovectors hold 
promise for overcoming current barriers and 
may open a new avenue for RNAi-based thera-
peutics.  Combining the multi-functionality in-
cluding the protection on nanovectors and 
RNAs, tissue and cell targeting, imaging, exter-
nal energy-assisted approaches and the con-
trolled release of RNAi would greatly improve 
the in vivo RNAi efficiency and efficacy, and 
would also be a powerful tool to gain insights 
into the gene regulation process.  Until recently, 
several multifunctional nanovectors have been 
designed to solve specific problems, however, 
the optimum organization of the functional 
moieties requires delicate design since some of 
these functional parts might interfere with each 
other and affect their functions.   
 
5. Fabrication of Gene-Nanoparticle Complex  
 
5.1. Basic requirements for RNA or DNA com-
plex formulation 
 
The RNAi nanovector complex could be con-
structed in many different ways.  Generally 
speaking, RNA-vector interaction is mediated by 
electrostatic interaction, and materials such as 
polycationic lipids, polymers and lipid-polymer 
complexes have been demonstrated to con-
dense negatively charged DNA/RNAs to form 
lipoplexes, polyplexes and lipopolyplexes, re-
spectively, and could also enhance the cellular 
uptake at the negatively charged cell mem-
brane.  Cationic polymers such as polyethyle-
neimine (PEI), polyamidoamine, and cationic 
dendrimers have been tested for RNAi delivery.  
Cationic peptides, poly-lysines, and arginine-
containing peptides have been successfully 
used as RNAs condensing and packaging vehi-
cles. However, cationic polymers such as 
polylysine and polyethyleneimine have shown to 
activate the complement system, and the in-
creased polycation length and surface charge 
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density leads to higher complement activation 
and/or cytotoxic effects due to electrostatic 
interactions with the negatively charged cell 
membrane.  
 
5.2. Possible adverse effects of therapeutic 
RNAi and ways to avoid them  
 
With commonly used cationic lipoplexes or poly-
plexes, RNAs were commonly attached onto the 
surface of the vector, putting the RNAs in con-
tact directly with environment and potentially 
increasing immune response or other adverse 
effects.  A recent study [146] reported the unex-
pected side effects of delivering siRNA in vivo.  
These adverse side effects include the induction 
of type I interferon response and saturation of 
endogenous RNAi pathway components.  The 
RNAi commonly used therapeutically is usually 
about 21 nucleotides [147, 148], and research 
have shown that siRNA with a length longer 
than 30 nucleotides could activate the host im-
mune system when administered at high con-
centration [149, 150].  
 
These adverse effects are presumably initiated 
by the toll-like receptors and the helicases RIG-1 
and Mda5.  In addition, protein kinase R also 
plays an important role in the recognition of 
siRNA by the immune system.  Other undesir-
able side effects may arouse from cross reac-
tions with the endogenous miRNA pathway, in 
which siRNA acts as miRNA and can interact 
with the 3’UTR of mRNAs by partial homology, 
inhibiting their translation without triggering 
their degradation [151, 152].  The dsRNAs 
could stimulate the interferon response when 
the sequence is longer than 30 nucleotides 
[153].  Researchers have attempted several 
approaches to avoid these adverse responses.  
In the RNAi sequence, modifications on siRNA 
could minimize the immune response.  Incorpo-
ration of 2’–O-methyl in the sugar structure, 
with both sense and antisense strands, has 
been shown to repress endonuclease activity.  
Other modifications such as the introduction of 
a phosphorothioate backbone linkage at the 3’-
end of the RNA strand, also reduce susceptibil-
ity to exonucleases.  
 
6. Conclusions and Future Direction  
 
Non-viral RNAi nanovectors have tremendous 
potential as effective carriers to overcome cur-
rent gene/drug delivery barriers.  Significant 
efforts have been directed towards solving spe-
cific problems and have attained huge achieve-
ments.  However, a comprehensive analysis and 
engineering of the nanovectors with respect to 
the tumor-targeted delivery and function proc-
ess has yet to be demonstrated.  The ultimate 
goal of the RNAi delivery system is to transport 
the relevant RNAi to all target cells safely and 
effectively, and thus trigger target gene regula-
tion.  Comprehensive consideration and optimi-
zation of RNAi nanovectors requires under-
standing of both bodily function mechanisms 
and physical microenvironment properties.  Mul-
tifunctional nanovectors able to identify loca-
tion, indicate efficiency, remain sensitive to the 
environment, and target delivery with high effi-
ciency would be a new generation of non-viral 
nanovectors and a carrier for diverse RNAi 
molecules.  Development in material engineer-
ing would further accelerate RNAi nanovectors 
fabrication. Biocompatible, non-toxic, functional 
and intelligent materials have demonstrated 
superiority and provide guidelines for material 
application in RNAi nanovectors.  Exterior-
energy controlled delivery of RNAi nanovectors 
have shown brilliant prospects and more and 
more delivery control systems are being devel-
oped to overcome current barriers.  However, 
although the mechanisms of the RNA interfer-
ence are becoming clearer, it is still far from 
fully understood and other physiological phe-
nomena also deserve further investigation to 
present a more detailed solution of the barriers.  
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